Ekso Bionics Prices $5.852 million Private Placement Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional

#EKSO Ekso Bionics Prices $5.852 million Private Placement

www.stocktitan.net/news/EKSO/ekso-bionics-p...

NEWS: ( NASDAQ: #EKSO ) Applied Digital Shares Surge on Bright Outlook. Is It Too Late to Buy the Stock?

#APLD #EKSO #CRWV #19b81da2-7f0b-4d2f-be4f-0d33295bab9d #investing #Technology #and #Telecom

Origin | Interest | Match

#EKSO on the radar after recent momentum. Volume looks good, and a slight run could be in store.

#EKSO momentum sparks profits, ChronoScale launch in sight

Today’s most cited tickers with positive sentiment (last 24h):

#CETX: 24
#TSLA: 21
#ASTS: 17
#SPY: 17
#NVDA: 13
#SLS: 11
#AMZN: 10
#OTLK: 8
#NKE: 8
#BTC: 7
#NXXT: 7
#SLV: 7
#EKSO: 7
#MREO: 6
#AAPL: 6
#MU: 6
#GOOG: 5
#GOOGL: 5

Most Searched, Tuesday December 30, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Dec 30th - #RR #JBLU #RXRX #SLS #BITF #DNN #BTBT #SOPA #BBAI #SIDU #CETX #EKSO #TRON #TLRY #RDW #ONDS #MDXH #HYMC #CERS #BYND - More: crystalequityresearch.com/most-searche... - #smallcap

Just In: ( NASDAQ: #EKSO ) Ekso Bionics Holdings Inc. (NASDAQ: EKSO) Sees Notable Increase in Tuesday Morning Market Activity

🤝 $EKSO +103% | Merges with $APLD cloud unit to form ChronoScale AI compute platform | Tiny exoskeleton company transforms into GPU-focused infrastructure player

🤝 $APLD spins cloud unit into ChronoScale with $EKSO | GPU platform for AI workloads | $75.2M trailing revenue | APLD retains 97% stake | Deal expected H1 2026 | Watch execution

Halper Sadeh LLC Urges Shareholders of EKSO, FOLD, WBD, and CFLT to Explore Their Legal Rights Halper Sadeh LLC is investigating potential securities law violations involving EKSO, FOLD, WBD, and CFLT and invites shareholders to discuss their rights.

Halper Sadeh LLC Urges Shareholders of EKSO, FOLD, WBD, and CFLT to Explore Their Legal Rights #United_States #New_York #WBD #Fold #EKSO

📢 Stocks Trending NOW: #CETX #RARE #BIDU #EKSO #PFSA #MREO #DRMA #BNAI #CROX #NEM

🤝 $APLD spins cloud unit to form ChronoScale with $EKSO | GPU compute platform for AI | APLD retains 97% | watch datacenter consolidation trend

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Dec 4th - #YB #NA #MAMO #LASE #DRMA #CNTX #SYBX #SVCO #PLRX #NDRA #KITT #EKSO #CBIO #BBNX #ZKH #NOAH #GCO #ECVT #BBW - More: crystalequityresearch.com/leading-indi... - #smallcap

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System Ekso Bionics (Nasdaq: EKSO) announced an exclusive U.S. distribution agreement with MediTouch to act as the authorized sales agent and distributor for the BalanceTutor™ rehabilitation system in the United States, dated December 4, 2025.The BalanceTutor uses a patented 4D perturbation treadmill with multiple force and movement sensors to simulate slips, trips, and stumbles while supporting patient weight via an overhead frame to promote safe reactive balance training in inpatient and outpatient rehabilitation settings.Ekso said the product is complementary to its enterprise health exoskeleton offerings and will be marketed through its existing customer call points to increase awareness and adoption across U.S. physical rehabilitation facilities.

#EKSO Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System

www.stocktitan.net/news/EKSO/ekso-bionics-i...

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Ekso Bionics (Nasdaq: EKSO) announced a registered direct offering entered on October 28, 2025 to sell 769,490 shares of common stock at $4.81 per share in an at-the-market transaction under Nasdaq rules.The offering is expected to close on or about October 30, 2025, with gross proceeds of approximately $3.7 million before placement agent fees and other offering expenses. Lake Street Capital Markets is the exclusive placement agent.The company intends to use net proceeds for general corporate purposes, including research and development, selling, general and administrative costs, strategic initiatives and working capital. The shares are being offered under a Form S-3 shelf registration declared effective June 20, 2023.

#EKSO Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

www.stocktitan.net/news/EKSO/ekso-bionics-a...

Ekso Bionics Reports Third Quarter 2025 Financial Results Ekso Bionics (Nasdaq: EKSO) reported Q3 2025 results on Oct 28, 2025: revenue $4.2M (up 2% YoY, up 105% sequentially), gross margin 60.3% (up 680 bps YoY, driven by higher Enterprise Health sales and lower device cost), and net loss $1.4M (improved 31% YoY, $0.54 per share). Operating expenses declined across S&M, R&D and G&A mainly due to Employee Retention Credit benefits.The company had $2.7M cash at Sept 30, 2025 and announced it is exploring strategic transactions, which may include divestiture or acquisition and could require substantial issuance of company securities.

#EKSO Ekso Bionics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/EKSO/ekso-bionics-r...

BREAKING NEWS: ( NASDAQ: #EKSO ) PRISM Mid-Day Movers: Reverse Split and Weak MedDevice Sales Pressure Indices

Ekso Revenue Falls 58 Percent in Q2 | The Motley Fool

#EKSO #b33912fa-a718-4341-b83c-aca750927392 #data-news

Origin | Interest | Match

Ekso Bionics Reports Second Quarter 2025 Financial Results Ekso Bionics (NASDAQ: EKSO), a leader in exoskeleton technology, reported its Q2 2025 financial results, showing significant challenges. Revenue declined to $2.1 million from $5.0 million in Q2 2024, primarily due to lower Enterprise Health device sales. The company posted a net loss of $2.7 million, or $1.24 per share.Despite challenges, Personal Health products grew over 50% year-over-year in H1 2025. Notable developments include naming Bionic P&O as first Ekso Indego Personal device distributor, joining NVIDIA Connect program for AI development, launching an AI voice agent for EksoNR, and introducing eksoUniversity for physical therapy education.Gross margin decreased to 40% from 53% year-over-year, while cash position stood at $5.2 million as of June 30, 2025.

#EKSO Ekso Bionics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/EKSO/ekso-bionics-r...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed Jun 18th - #SNTI #INV #IMDX #EKSO #DXLG #BNTC #ACB #DDD #BPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

AI Breakthrough: Ekso Bionics Unveils Voice-Controlled Medical Exoskeletons Using NVIDIA Tech New AI voice agent transforms exoskeleton control, leveraging 350,000 patient sessions and 15M data points. See how NVIDIA partnership accelerates medical robotics innovation.

#EKSO Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

www.stocktitan.net/news/EKSO/ekso-bionics-a...

Ekso Bionics Announces New Effective Date of Reverse Stock Split Ekso Bionics (NASDAQ: EKSO) has announced a revised effective date for its previously approved 1-for-15 reverse stock split, now scheduled for June 2, 2025, at 12:01 a.m. Pacific time. The company's outstanding shares will decrease from approximately 35.5 million to 2.4 million shares post-split. This action follows a Nasdaq non-compliance notice received in December 2024 regarding the minimum bid price requirement. The reverse split aims to raise the stock's trading price to meet Nasdaq's $1.00 minimum bid requirement for at least ten consecutive trading days. The split will affect all issued shares, including adjustments to stock options, warrants, and RSUs, with fractional shares being rounded up to the next whole share.

#EKSO Ekso Bionics Announces New Effective Date of Reverse Stock Split

www.stocktitan.net/news/EKSO/ekso-bionics-a...

Just In: ( NASDAQ: #EKSO ) PRISM Mid-Day Movers: Pharma Shifts and Share Structure Headlines

Midday Movers:
#IXHL surges 27% after scrapping 50% of its Series A Warrants — that's 175M+ potential shares off the table. A bold dilution cut ahead of key sleep apnea data.
#EKSO slides 17% after announcing a 1-for-15 reverse split to maintain Nasdaq compliance.
prismmarketview.com/prism-mid-da...

Ekso Bionics Announces Reverse Stock Split Ekso Bionics (NASDAQ: EKSO) has announced a 1-for-15 reverse stock split effective May 27, 2025. The split will reduce outstanding common stock from approximately 35,289,695 to 2,352,646 shares. The primary purpose is to raise the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for at least ten consecutive trading days.The reverse split, approved by shareholders on May 16, 2025, will affect all issued shares, including adjustments to stock options, warrants, and restricted stock units. No fractional shares will be issued, with any fractional shares being rounded up. The company will maintain its "EKSO" trading symbol but will trade under a new CUSIP number 282644 400.

#EKSO Ekso Bionics Announces Reverse Stock Split

www.stocktitan.net/news/EKSO/ekso-bionics-a...

Breakthrough: Ekso Bionics Partners With NVIDIA to Create Revolutionary AI-Powered Rehabilitation Technology Medical device leader joins elite NVIDIA program to develop first-ever AI foundation model for physical rehabilitation. Learn how this breakthrough transforms patient care.

#EKSO Ekso Bionics Accepted into NVIDIA Connect Program

www.stocktitan.net/news/EKSO/ekso-bionics-a...

Ekso Bionics Reports First Quarter 2025 Financial Results Ekso Bionics (NASDAQ: EKSO) reported its Q1 2025 financial results, showing a revenue decline to $3.4 million from $3.8 million in Q1 2024. The company announced two strategic partnerships: naming National Seating & Mobility (NSM) as exclusive Ekso Indego Personal device distributor in the U.S. CRT industry, and Bionic Prosthetics & Orthotics Group as its first distributor in the orthotics and prosthetics sector. Gross margin improved to 53.5% from 51.9%. Net loss narrowed to $2.9 million ($0.12 per share) compared to $3.4 million ($0.20 per share) in Q1 2024. The company improved its operating cash burn by 43% and secured $3.8 million from warrant exercises, ending the quarter with $8.1 million in cash and restricted cash.

#EKSO Ekso Bionics Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/EKSO/ekso-bionics-r...

Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results Ekso Bionics (NASDAQ: EKSO) reported its Q4 and full-year 2024 financial results, achieving record Q4 revenue of $5.1 million, up 5% year-over-year. Q4 gross margin improved by 400 basis points to 53%. The company recently named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor in the U.S.For full-year 2024, revenue was $17.9 million, down 2% from 2023. Gross profit reached $9.5 million with a 53% margin. Net loss improved by 25% to $11.3 million ($0.56 per share) compared to $15.2 million in 2023. Operating expenses decreased across all categories, with cash usage improving to $9.8 million from $12.1 million in 2023. The company ended 2024 with $6.5 million in cash and restricted cash.

#EKSO Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

www.stocktitan.net/news/EKSO/ekso-bionics-r...

Leading Mobility Provider NSM Takes Control of EKSO's Groundbreaking Exoskeleton Distribution Ekso Bionics partners with NSM as exclusive U.S. distributor for Indego Personal, expanding access to advanced mobility solutions through insurance networks.

#EKSO NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry

www.stocktitan.net/news/EKSO/nsm-named-excl...